Motesanib
(Redirected from Motesanib diphosphate)
Motesanib is a small molecule inhibitor targeting multiple receptor tyrosine kinases (RTKs), particularly those involved in the angiogenesis and cell proliferation pathways. It is primarily investigated for its potential use in the treatment of various types of cancer, including thyroid cancer, lung cancer, and breast cancer. Motesanib works by inhibiting the activity of specific kinases, such as the vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and stem cell factor receptor (c-KIT), which play critical roles in tumor growth and metastasis.
Mechanism of Action
Motesanib diphosphate inhibits the kinase activity of VEGFR1, VEGFR2, and VEGFR3, PDGFR, and c-KIT. By blocking these receptors, motesanib prevents the activation of the signaling pathways that promote tumor angiogenesis (the formation of new blood vessels that supply the tumor with nutrients and oxygen) and cell proliferation. This inhibition can lead to the reduction of tumor growth and potentially shrink the tumor size.
Clinical Trials
Motesanib has been evaluated in several clinical trials for its efficacy and safety in treating various cancers. One of the notable Phase III trials is the MONET1 (Motesanib NSCLC Efficacy and Tolerability Study), which focused on patients with non-small cell lung cancer (NSCLC). However, the results have shown mixed outcomes, and the development of motesanib for NSCLC was discontinued after it failed to meet the primary endpoint of improved overall survival.
In thyroid cancer, motesanib has shown promise in early-phase trials, particularly in patients with progressive, locally advanced, or metastatic differentiated thyroid cancer. It demonstrated significant tumor shrinkage and a manageable safety profile, indicating potential as a therapeutic option for this patient population.
Adverse Effects
The use of motesanib is associated with several adverse effects, which are common to angiogenesis inhibitors. These include hypertension, fatigue, diarrhea, nausea, and weight loss. More severe but less common side effects may include hepatotoxicity (liver damage), thromboembolism (blood clots), and gastrointestinal perforation.
Current Status
As of the last update, motesanib is not yet approved by any regulatory agency for the treatment of cancer. Research and development continue, with ongoing trials exploring its use in different cancer types and in combination with other therapies. The future of motesanib as a cancer treatment depends on the outcomes of these studies and its ability to demonstrate a favorable balance between efficacy and safety.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD